Circio: TG01 approved for clinical studies - Redeye

Circio's partner IOVaxis received approval to initiate clinical development of the cancer vaccine TG01 in China on March 1. This should trigger a USD3m milestone payment within two weeks as IOVaxis licenses TG01 in China, Hong Kong, Macau, and Singapore, which will be a welcome source of funding for Circio, prolonging the financial runway.

Länk till analysen i sin helhet: https://www.redeye.se/research/988565/circio-tg01-approved-for-clinical-studies?utm_source=finwire&utm_medium=RSS